Background: Biologic agents are routinely used in the treatment of severe psoriasis. The evaluation of treatment response is mainly based on the physician's global clinical assessment.
Introduction
The induction of biologic agents targeting immunologic alterations of psoriasis significantly changed the management of the disease. With gathering evidence and experience on their safety and efficacy, these agents acquired an important role in the management of psoriatic patients, and their use expanded worldwide [1] . The assessment of response to treatment with biologics is mainly based on the calculation of the PASI score, which is almost universally used in studies and clinical trials [2] . In daily practice, the application of PASI score is restricted by its complexity, and the routine evaluation of treatment is typically based on the physician's global assessment and the patient's perspective, which is typically quantified with the DLQI form [2, 3] .
Dermoscopy represents an easily applicable clinical diagnostic method of well-documented value for the diagnosis of skin tumors [4] . In addition, dermoscopy has been shown to be a valuable tool for monitoring response of skin cancer to topical treatment, especially after the application of nonsurgical modalities [5] . This is because it allows the visualization of alterations occurring in sub-macroscopical structures as a result of the applied treatment.
More recently, the application of dermoscopy expanded also to the field of inflammatory and infectious skin diseases [6] [7] [8] [9] . There is mounting evidence that dermoscopy enhances the differential diagnosis between psoriasis and other inflammatory dermatoses, such as dermatitis, lichen planus and pityriasis rosea [6] . Furthermore, it has been assumed that dermoscopy might also be useful for monitoring the response of psoriasis to systemic drugs by providing early signs of response to treatment and by revealing residual disease or recurrence before it becomes clinically evident [8] . Undoubtedly, such beneficial results of dermoscopy would be clinically relevant, providing clinicians early information on disease activity, thereby helping them to optimize patient treatment management. However, this hypothesis has not been tested up to date.
The aim of this study was to investigate whether dermoscopic criteria observed in psoriatic lesions of patients under treatment with biologics could improve the assessment of the response to the applied treatment.
Methods
This was a prospective multicentric study conducted in three 
Statistical analysis
The patients' sex, drug administered, higher probability for partial response 
Discussion
Our results suggest that dermoscopy is useful in assessing and predicting treat- by a lack of clinical-dermoscopic correlation. Specifically, although clinically assessed as completely responding, they dermoscopically displayed dotted vessels (minimal or in clusters). Indeed, at the subsequent visit they recurred also
clinically. An early recognition of disease recurrence might be particularly relevant, since strategies to reinforce the drug efficacy do exist.
In conclusion, our results provide an initial indication that dermoscopy might be useful for evaluating the response of psoriatic patients to biologic agents. Hemorrhagic dots represent an early predictor of subsequent clinical response, while the persistence or reappearance of dotted vessels might predict a subsequent clinical recurrence. This information might improve the assessment of disease activity and serve the goal of prolonging the survival of biologic agents.
